Spago Nanomedical AB

Equities

SPAG

SE0004899474

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 08:35:44 31/05/2024 pm IST			5-day change	1st Jan Change
0.293 ^SEK	+1.03%		+22.08%	-10.40%

20/05	Spago Nanomedical Provides an Update on Tumorad-01, Trial Proceeds as Planned	CI
02/05	Spago Nanomedical AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

BioStock: Spago's CEO - "Advancing the Tumorad programme comes first"

May 07, 2024 at 12:17 pm IST

Spago Nanomedical's Q1 report signals steady progress with its radiopharma pipeline. Lead programme Tumorad recently got a boost by the release of positive non-clinical data in a triple-negative breast cancer model, incentivising the company to strengthen its management.

- 2024 has begun in the same positive spirit as we ended last year. Given the progress within both of our development programmes, we have seen a need to strengthen the company's organisation, says Spago's CEO Mats Hansen.

Read the article at biostock.se:

Spago's CEO: Advancing the Tumorad programme comes first - BioStock

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

https://news.cision.com/spago/r/biostock--spago-s-ceo----advancing-the-tumorad-programme-comes-first-,c3974196

Latest news about Spago Nanomedical AB

Spago Nanomedical Provides an Update on Tumorad-01, Trial Proceeds as Planned	20/05	CI
Spago Nanomedical AB Reports Earnings Results for the First Quarter Ended March 31, 2024	02/05	CI
Spago Nanomedical AB Reports Favorable Data in Breast Cancer Model with Tumorad	24/04	CI
Spago Nanomedical AB Announces Appointment of Birgitta Rembratt Svensson as Head of CMC & Supply, Effective June 1, 2024	16/04	CI
Spago Nanomedical AB Reports Earnings Results for the Full Year Ended December 31, 2023	07/02	CI
Spago Nanomedical AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	07/02	CI
Spago Nanomedical Proceeds to the Next Dose Level in the Phase I/IIa Study Tumorad-01	10/01	CI
Spago Nanomedical Announces Positive Top Line Data from a Clinical Phase IIa Study in Patients with Endometriosis	20/12	CI
Spago Nanomedical Reports Positive Top Line Data from Clinical Phase IIa Study SPAGOPIX-02 in Patients with Endometriosis	15/12	CI
Spago Nanomedical AB Announces First Patient Dosed in Spago Nanomedical's Clinical Phase I/IIA Study Within the Tumorad(R) Program	07/12	CI
Spago Nanomedical AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	03/11	CI
Spago Nanomedical AB Announces Publication of Four New Patent Applications Filed with the European Patent Office	24/23/24	CI
Spago Nanomedical Announces Cancer Therapy Approved for Phase I/IIa	23/23/23	CI
Spago Nanomedical AB Receives Approval to Initiate the Clinical Phase I/IIa Study with Tumorad in Australia	19/23/19	CI
Spago Nanomedical AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	31/23/31	CI
Spago Nanomedical Updates on the Clinical Phase IIa Study SPAGOPIX-02	28/23/28	CI
Spago Nanomedical AB Announces Establishment of A Scientific Advisory Board	13/23/13	CI
Spago Nanomedical AB Submits Application to Start Tumorad(R) Clinical Phase I/IIa Study	23/23/23	CI
Spago Nanomedical AB Elects New Directors	10/23/10	CI
Spago Nanomedical AB Reports Earnings Results for the First Quarter Ended March 31, 2023	09/23/09	CI
Spago Nanomedical AB Announces Board Resignations	05/23/05	CI
Spago Nanomedical AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	02/23/02	CI
Spago Nanomedical AB Publishes Scientific Paper on Positive Preclinical Data with Tumorad(R) as Treatment of Solid Tumors	10/23/10	CI
First Patient Dosed in Spago Nanomedical’S Endometriosis Phase Iia Clinical Study	08/22/08	CI
Spago Nanomedical Initiates Clinical Trial with Spagopix in Endometriosis and Concludes SpagoPix -01	06/22/06	CI

Chart Spago Nanomedical AB

Duration

Period

More charts

Company Profile

Spago Nanomedical publ AB, formerly Spago Imaging publ AB, is a Sweden-based biotechnology company. It specialized in the areas of contrast agents and nanoscale life science research. The Company is involved in three projects: Spago Pix, a nanomaterial developed for use as a cancer selective contrast agent for Magnetic Resonance Imaging (MRI); the therapeutic project Tumorad, using nanoparticles loaded with radionuclides for selective treatment of cancers, which are unsuitable for surgery or external radiation; and Archaea Platin, aimed at delivering of chemotherapeutic substance cisplatin selectively to tumors in order to reduce side effects on healthy tissue. The Company's technology comprises a technology platform IonXgel, which is a nano-sized biocompatible material consisting of polar polymers; a protein-based drug delivery platform, ProtRc; and 3PEG, a platform which enables attachment of polyethylene glycol (PEG) derivatives to small molecules (PEGylation).

Sector

Biotechnology & Medical Research

Calendar

10/06/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Spago Nanomedical AB

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Diagnostics & Testing

	1st Jan change	Capi.
SPAGO NANOMEDICAL AB	-10.40%	62.5L
EXACT SCIENCES CORPORATION	-38.56%	838.69Cr
GUARDANT HEALTH, INC.	+0.18%	331.62Cr
IOVANCE BIOTHERAPEUTICS, INC.	+9.29%	248.63Cr
BGI GENOMICS CO., LTD.	-18.21%	205.7Cr
VERACYTE, INC.	-24.57%	158.63Cr
MARAVAI LIFESCIENCES HOLDINGS, INC.	+32.37%	115.16Cr
SEEGENE, INC.	-7.64%	70Cr
CAREDX, INC	+8.42%	68Cr
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-29.59%	51Cr

Bio Diagnostics & Testing